| Document |
Document Title |
|
WO/2023/057613A1 |
The present invention relates to benzimidazole derivatives and pharmaceutical compositions comprising such benzimidazole derivatives, for use in the treatment or prevention of a histiocytosis or a craniopharyngioma.
|
|
WO/2023/057386A1 |
The present application relates to compositions comprising sialic acid and/or fucose to enhance cognitive function by promoting differentiation of oligodendrocyte precursor cells into mature, myelinating oligodendrocytes.
|
|
WO/2023/058731A1 |
A skin care composition for suppressing the formation of wrinkles that are caused by photoaging, said composition including a pyrimidine nucleotide or a precursor thereof as an active ingredient.
|
|
WO/2023/059099A1 |
Provided are: a pharmaceutical composition for preventing, improving, alleviating, or treating pulmonary fibrosis, the composition comprising Ezetimibe or a salt thereof as an active ingredient; a health functional food composition; a me...
|
|
WO/2023/059121A1 |
The present invention provides a benzofuranyl hydroxyphenyl methanone derivative compound having a specific chemical structure, a HSP47-inhibitory pharmaceutical compound comprising a pharmaceutically acceptable salt thereof, and a prepa...
|
|
WO/2023/058975A1 |
The present invention provides a pharmaceutical composition for inhibiting HSP47, the composition including a benzofuranyl hydroxyphenyl methanone derivative compound having a specific chemical structure, or a pharmaceutically acceptable...
|
|
WO/2023/057879A1 |
Methods and products for treating a subject diagnosed with an autism spectrum disorder, an intellectual disability, an anxiety disorder, a mood disorder, a disorder of social interaction, irritability, aggression, self-injurious behavior...
|
|
WO/2023/059160A1 |
The present invention relates to a fusion protein of albumin and retinol-binding protein that can be used to prevent or treat fibrotic diseases occurring in the liver, pancreas, lung, or the like. The fusion protein of the present invent...
|
|
WO/2023/059899A1 |
The present application discloses novel compounds, pharmaceutical compositions containing these compounds and methods of inducing degradation of a protein, comprising contacting the protein with an effective amount of a compound of the d...
|
|
WO/2023/053731A1 |
Provided is a composition which contains barley young leaves and is used for increasing regulatory T cells, suppressing an immune response and maintaining a normal immune function and for anti-viral purposes.
|
|
WO/2023/054712A1 |
The present invention pertains to a peptide and a composition containing the peptide. The peptide according to the present invention has an amino acid sequence F-Nal1-V-V-N-V-Y-D-D-PeG-V-Nal1-Y-H-V-C-G (SEQ ID NO. 2) or has an amino acid...
|
|
WO/2023/053715A1 |
Provided is a composition comprising Chlamydomonas reinhardtii or an extract of the Chlamydomonas reinhardtii, wherein the Chlamydomonas reinhardtii or the extract of the Chlamydomonas reinhardtii functions as an antagonist of an adrener...
|
|
WO/2023/054549A1 |
The present invention provides a novel compound that induces selective degradation of a non-receptor tyrosine kinase (and especially a tyrosine kinase that constitutes the JAK family), or a pharmaceutically acceptable salt thereof. Provi...
|
|
WO/2023/054706A1 |
The present invention provides a conjugate of an antibody and a functional substance, said conjugate having excellent desired properties, or a salt thereof. More particularly, the present invention provides a conjugate of an antibody and...
|
|
WO/2023/054006A1 |
Provided are an opioid receptor antagonist, which contains, as an active ingredient, one atropisomer between a pair of atropisomers of a compound represented by formula (1), said atropisomer having an opioid receptor antagonistic action,...
|
|
WO/2023/054423A1 |
The disclosure provides uses of multispecific antigen-binding molecules that targets human DLL3 for the treatment of cancers.
|
|
WO/2023/054241A1 |
The present invention provides a lipid nanoparticle used for delivering a nucleic acid to brain tissue. The lipid nanoparticle contains: an ionizable lipid represented by formula (1) (the meanings of the reference symbols in formula (1) ...
|
|
WO/2023/053272A1 |
The disclosure provides uses of multispecific antigen-binding molecules that targets human DLL3 for the treatment of cancers.
|
|
WO/2023/055124A1 |
The present invention provides a bicyclic fused ring (for example, benzo[d]imidazole, benzo[d][1,2,3]triazole, or 8-oxo-8,9-dihydro-7H-purine) derivative or a pharmaceutically acceptable salt thereof, a method for preparing same, a pharm...
|
|
WO/2023/054292A1 |
The present invention provides a pharmaceutical composition containing a compound that exhibits a coronavirus growth inhibitory activity. A pharmaceutical composition containing a compound represented by the formula (wherein: Y is N; R1 ...
|
|
WO/2023/054243A1 |
The present invention provides lipid nanoparticles containing a ligand having cell directivity bonded to an activated PEG lipid and an ionic lipid (the definitions of the symbols in the formula are as described in the description) repres...
|
|
WO/2023/053282A1 |
The present disclosure provides: an anti-cancer agent that contains multispecific antigen-binding molecules, said anti-cancer agent being capable of effectively and selectively mobilizing T cells to target cancer cells, i.e. to cells tha...
|
|
WO/2023/054669A1 |
The present disclosure pertains to an ophthalmological composition containing: (A) zinc chloride; and (B) a polyvinyl polymer compound.
|
|
WO/2023/056033A1 |
Disclosed herein are novel lipids that can be used in combination with other lipid components, such as helper lipids, structural lipids, and cholesterols, to form lipid nanoparticles for delivery of therapeutic agents, such as nucleic ac...
|
|
WO/2023/053315A1 |
This PD-1 expression inhibitor contains at least one component selected from the group consisting of the following (a) through (d): (a) interleukin 36 or a modified form thereof; (b) a polynucleotide having a nucleotide sequence encoding...
|
|
WO/2023/052829A1 |
The present invention relates to a biotransformation process effected by cultures of a microbial consortium for the preparation of a Quillaja plant extract with antibacterial and cytotoxic properties, comprising one or more monodesmosidi...
|
|
WO/2023/054732A2 |
The present invention provides a pharmaceutical composition containing a coronavirus 3CL protease inhibitor in order to treat a novel coronavirus (COVID-19) infection. Provided is a pharmaceutical composition for treating a novel coronav...
|
|
WO/2023/054168A1 |
Provided is a water-in-oil composition for external use that contains ascorbic acid or a salt thereof. This prepared water-in-oil composition for external use contains: (A) at least one selected from the group consisting of ascorbic acid...
|
|
WO/2023/054421A1 |
The present disclosure provides: an anti-cancer agent that contains multispecific antigen-binding molecules, said anti-cancer agent being capable of effectively and selectively mobilizing T cells to target cancer cells, i.e. to cells tha...
|
|
WO/2023/054590A1 |
Provided is an althaea-derived material that has been improved in order to enhance the activity. The starting material for the fermented product is althaea or a processed material therefrom, and the fermented product is provided by one...
|
|
WO/2023/048111A1 |
A problem addressed by the present invention is to provide a vaccine effective in preventing infection by Streptococcus spp. that cause mastitis in livestock, etc. Specifically, the present invention provides a vaccine that contains a no...
|
|
WO/2023/048152A1 |
The present invention provides: a compound having a serotonin 5-HT2A receptor antagonist and/or inverse agonist activity or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing same. A compound represen...
|
|
WO/2023/047708A1 |
An anti-aging agent that includes K11H[(VO)3(SbW9O33)2] and/or Na9[SbW9O33].
|
|
WO/2023/048230A1 |
The purpose of the present invention is to provide a method having a superior anti-tumor effect. [Solution] A therapy device kit having an anti-cancer drug for inducing immunogenic cell death and an administration device capable of admin...
|
|
WO/2023/046713A1 |
An aspect is a method of improving sleep quality and/or subsequent behavioural outcomes. Another aspect is amethod of treating, preventing, and/or reducing at least one of risk, incidence or severity of at least one condition for which i...
|
|
WO/2023/045371A1 |
Disclosed is a novel cationic lipid compound represented by formula (A), or an isomer, an N-oxide, a pharmaceutically acceptable salt, or a prodrug thereof. Further disclosed are a preparation method, a composition and an application of ...
|
|
WO/2023/049258A1 |
The present disclosure provides to linker compounds of Formula (I) or (II): pharmaceutically acceptable salts thereof, and related scaffolds and conjugates. More specifically, compounds of formula (l-A) are disclosed. The present disclos...
|
|
WO/2023/047810A1 |
The present invention addresses the problem of providing a regulator for primary cilia of immune-related cells and a technique for the use thereof. Use is made of a regulator for primary cilia of immune-related cells that contains at lea...
|
|
WO/2023/045910A1 |
The present application discloses a small-molecule compound having a naphthol ether structure, and a use thereof. Disclosed in the present application are a compound having a structure represented by general formula (I), a pharmaceutical...
|
|
WO/2023/048299A1 |
Provided is a regulator of cell membrane scrambling (e.g., cell membrane scrambling induced by extracellular ATP stimulation), said regulator containing at least one regulator selected from the group consisting of XK expression regulator...
|
|
WO/2023/046715A1 |
The present invention generally relates to the use of a mulberry extract to improve sleep quality and/or subsequent behavioural outcomes. More particularly, the present disclosure relates to administration of a supplement comprising a mu...
|
|
WO/2023/042902A1 |
The present invention relates to a promoter for differentiation into a cartilage cell, a cartilage cell propagation promoter, and a cartilage matrix production promoter that contain a liquiritigenin glycoside. The present invention can...
|
|
WO/2023/040818A1 |
Disclosed are a RIPK1 inhibitor that inhibits programmed cell necrosis and a preparation method therefor. The disclosed RIK1 inhibitor is represented by general formula I, where X1, X2, X3, X4, X5, Z1, Z2, Z3, L1, L2, L3, R, R1, ring D a...
|
|
WO/2023/042879A1 |
The present invention provides: a compound having coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing same. Provided is a compound represented by formula...
|
|
WO/2023/042158A1 |
Uses of anamorelin for improving patient reported outcomes in anorexia / cachexia patients, particularly based on patient populations who benefit from such use, and methods for defining and providing clinically meaningful treatment effects.
|
|
WO/2023/042851A1 |
A compound useful for preventing or treating dry eye and a medicament for preventing and/or treating dry eye comprising the same which does not substantially impact on the intraocular pressure are provided. The present invention relates ...
|
|
WO/2023/043444A1 |
Methods and compositions for treating cancer (e.g., ovarian, fallopian tube, uterine, cervical, vaginal, vulvar, or peritoneal cancer) are disclosed. The methods include intermittent administration of a glucocorticoid receptor modulator ...
|
|
WO/2023/042876A1 |
A problem addressed is to provide a double-stranded nucleic acid complex with reduced central nervous system toxicity. Provided is a double-stranded nucleic acid complex including a first nucleic acid strand and a second nucleic acid s...
|
|
WO/2023/042888A1 |
The present invention provides a pharmaceutical composition for treating cognitive decline. The pharmaceutical composition includes an AMPA receptor antagonist. The present invention also provides a pharmaceutical composition for treatin...
|
|
WO/2023/038088A1 |
The present invention provides a trisulfide-compound-containing agent for inhibiting nitration of tyrosine residues in hepatocyte growth factor, the trisulfide compound being: glutathione trisulfide or a pharmaceutically acceptable salt ...
|
